CoChat

Established and emerging roles peptide YY (PYY) and exploitation in obesity-diabetes

Open access
Lafferty, Ryan A., Flatt, Peter R., Irwin, Nigel · 2021 · Current Opinion in Endocrinology, Diabetes & Obesity

The DOI matches its Crossref record; 66 of the 69 references it cites were found in a registry or an index.

Abstract

Purpose of review: The antiobesity effects of activation of hypothalamic neuropeptide Y2 receptors (NPYR2) by the gut-derived hormone, peptide YY (PYY), are established. However, more recent insight into the biology of PYY has demonstrated remarkable benefits of sustained activation of pancreatic beta-cell NPYR1, that promises to open a new therapeutic avenue in diabetes. Recent findings: The therapeutic applicability of NPYR2 agonists for obesity has been considered for many years. An alternative pathway for the clinical realisation of PYY-based drugs could be related to the development of NPYR1 agonists for treatment of diabetes. Thus, although stimulation of NPYR1 on pancreatic beta-cells has immediate insulinostatic effects, prolonged activation of these receptors leads to well defined beta-cell protective effects, with obvious positive implications for the treatment of diabetes. In this regard, NPYR1-specific, long-acting enzyme resistant PYY analogues, have been recently developed with encouraging preclinical effects observed on pancreatic islet architecture in diabetes. In agreement, the benefits of certain types of bariatric surgeries on beta-cell function and responsiveness have also been linked to elevated PYY secretion and NPY1 receptor activation. Summary: Enzymatically stable forms of PYY, that selectively activate NPYR1, may have significant potential for preservation of beta-cell mass and the treatment of diabetes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/med.0000000000000612

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 66 references

Cited by

See all 42

Metadata

Authors
Lafferty, R. A., Flatt, P. R., & Irwin, N.
Affiliations
University of Ulster (GB)
Corresponding author
Irwin, Nigel
Venue
Current Opinion in Endocrinology, Diabetes & Obesity
Published
2020-12-30
Volume
28
Issue
2
Pages
253-261
ISSN
  • 1752-296X (ISSN-L)
  • 1752-2978
OpenAlex
W3120340222
Cited by
42
References
69
Citations by year
2026: 1 · 2025: 6 · 2024: 6 · 2023: 10 · 2022: 14 · 2021: 5
FWCI
1.65
Type
journal article
Language
en
Open access
Licence
other-oa
Locations
  • Current Opinion in Endocrinology Diabetes and Obesity (publishedVersion)
  • PubMed (publishedVersion)
  • Ulster University Research Portal (Ulster University) (submittedVersion, other-oa)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
peptide YY, pancreatic beta cells, obesity, diabetes mellitus, insulin secretion, beta-cell protection, bariatric surgery
MeSH terms
Diabetes Mellitus, Humans, Islets of Langerhans, Obesity, Peptide YY, Insulin-Secreting Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Established and emerging roles peptide YY (PYY) and exploitation in obesity-diabetes. https://app.cochat.ai/papers/10.1097/med.0000000000000612
The paper
Lafferty, R. A., Flatt, P. R., & Irwin, N. (2021). Established and emerging roles peptide YY (PYY) and exploitation in obesity-diabetes. Current Opinion in Endocrinology, Diabetes & Obesity. https://doi.org/10.1097/med.0000000000000612

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.